Jefferies Financial Group Inc. Buys Shares of 245,254 Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Key Points

• Jefferies Financial Group Inc. has acquired 245,254 shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in Q1, totaling approximately $341,000 and representing 0.12% ownership of the company.
• Wall Street analysts are optimistic, with multiple firms increasing their target prices for TSHA and a consensus price target of $8.17, reflecting a generally positive outlook.
• Taysha Gene Therapies reported earnings in May 2023, showing a revenue of $2.30 million for the quarter, surpassing analyst expectations of $1.48 million.

Jefferies Financial Group Inc. acquired a new stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 245,254 shares of the company's stock, valued at approximately $341,000. Jefferies Financial Group Inc. owned approximately 0.12% of Taysha Gene Therapies as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of TSHA. Octagon Capital Advisors LP grew its stake in Taysha Gene Therapies by 128.6% during the 4th quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company's stock valued at $18,078,000 after purchasing an additional 5,877,778 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in Taysha Gene Therapies during the 4th quarter valued at approximately $8,650,000. Bank of America Corp DE grew its stake in Taysha Gene Therapies by 1,178.9% during the 4th quarter. Bank of America Corp DE now owns 1,710,303 shares of the company's stock valued at $2,959,000 after purchasing an additional 1,576,568 shares in the last quarter. Norges Bank acquired a new stake in Taysha Gene Therapies during the 4th quarter valued at approximately $2,528,000. Finally, Avoro Capital Advisors LLC grew its stake in Taysha Gene Therapies by 7.2% during the 4th quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company's stock valued at $34,600,000 after purchasing an additional 1,349,999 shares in the last quarter. Institutional investors and hedge funds own 77.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Needham & Company LLC restated a "buy" rating and set a $8.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, July 1st. Citigroup reaffirmed an "outperform" rating on shares of Taysha Gene Therapies in a report on Thursday, May 29th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Monday, April 28th. Bank of America started coverage on Taysha Gene Therapies in a report on Friday, July 11th. They set a "buy" rating and a $8.00 target price on the stock. Finally, Canaccord Genuity Group increased their target price on Taysha Gene Therapies from $9.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, June 3rd. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $8.17.

Insider Activity

In related news, major shareholder Paul B. Manning purchased 750,000 shares of the business's stock in a transaction that occurred on Friday, May 30th. The shares were acquired at an average price of $2.75 per share, with a total value of $2,062,500.00. Following the acquisition, the insider owned 2,841,704 shares in the company, valued at approximately $7,814,686. This trade represents a 35.86% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 3.78% of the company's stock.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA traded up $0.15 during mid-day trading on Tuesday, hitting $2.91. The company had a trading volume of 2,350,722 shares, compared to its average volume of 2,861,643. The stock has a market cap of $623.59 million, a price-to-earnings ratio of -8.54 and a beta of 0.98. Taysha Gene Therapies, Inc. has a 12 month low of $1.05 and a 12 month high of $3.31. The company has a debt-to-equity ratio of 0.77, a current ratio of 5.35 and a quick ratio of 5.35. The firm's 50 day simple moving average is $2.59 and its two-hundred day simple moving average is $2.08.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $2.30 million for the quarter, compared to the consensus estimate of $1.48 million. Taysha Gene Therapies had a negative return on equity of 104.93% and a negative net margin of 1,201.08%. During the same quarter last year, the business posted ($0.10) EPS. As a group, equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.